Drug Discovery Assays

Drug Discovery Assay Kits: Comprehensive & Reliable Screening Solutions

Rapidly screen therapeutic candidates today and accelerate drug development decisions for a better tomorrow.

With INDIGO’s Drug Discovery Assay Kits, you can:

Read More About Drug Discovery with INDIGO nuclear-resp-related-img1

Showing 1–10 of 102 results

Evaluate Drug Candidates’ Safety from Every Angle with INDIGO’s Drug Discovery Assays

Did you know that almost 90% of candidate drugs fail in the first stage of trials?
Your drug lead can reverse the trend!

With INDIGO’s in vitro drug discovery assays, save resources and energy by identifying and characterizing adverse effects and potential risks before your drug candidate progresses further in the drug development process.

Explore INDIGO’s in vitro solutions in the broad categories of Prospective Screens, Safety Pharmacology, and Retrospective Screens, and start focusing your efforts on the best drug leads only.

drug-discovery-assasy-1-660X442

Prospective Screens

Explore drug-drug interactions with INDIGO’s Nuclear Receptor Profiling and accurately predict the adverse effects of your molecule of interest.

Or dig deeper downstream of nuclear receptor activation through quantification of gene expression using INDIGO’s assay services.

Learn more about INDIGO’s Gene Expression Profiling Services drug-discovery-assay-2

Safety Pharmacology

Evaluate your compounds on major receptors with INDIGO’s reporter assay panels to understand their biological and toxicological effects better.

Identify therapeutic agents with the highest selectivity and lowest potential for off-target and unwanted effects with INDIGO’s cell-based receptor assays.

Learn more about INDIGO’s Reporter Assay Services drug-discovery-assay-3

Retrospective Screens

Unexpected results from clinical trials or animal studies? Trouble-shoot with INDIGO’s large portfolio of ortholog assays to quickly determine if the response observed in laboratory animals is concordant with humans.

Learn more about INDIGO’s Ortholog Assays

Explore Additional INDIGO’s in vitro Solutions to Improve Drug Discovery

repoeter_assay_dieses

Disease State Targets

Quickly gain insights into the mechanisms underlying the involvement of key receptors in various diseases with INDIGO’s reporter assays.

drug-discovery-assay-5-min

Functional Classifications

Understand a compound’s on- and off-target effects and liabilities on overlapping pathways with nuclear receptors functional classifications.

Frequently Asked Questions

Do I need any special equipment to utilize INDIGO’s assay kits?

Each kit includes luciferase reporter cells, an assay plate, all required reagents (optimized culture media, positive-control agonist, and detection reagent), and a detailed Technical Manual. A luminometer is required for Relative Light Unit (RLU) measurements.

Do INDIGO’s Nuclear Receptor Assay Kits use stable cell lines or transiently transfected cells?

INDIGO’s Nuclear Receptor Assay Kits use transiently transfected cells, less prone to genetic drift and batch-to-batch variations. Moreover, they do not require cell culture, significantly reducing time and contamination risks. Simply thaw the reporter cells, and you are ready to perform the assay.

Can INDIGO’s Nuclear Receptor Assay Kits be used for diagnostic purposes?

INDIGO’s Nuclear Receptor Assay Kits are not for diagnostic purposes.

What is the best way to normalize data (e.g., cell number, protein content)?

We do not recommend normalizing RLU data to cell numbers or protein content. The suspension of reporter cells is a ‘master reagent’ that should be dispensed with high precision into all assay plate wells. Any significant downstream variability in cell number or health will result from cytotoxicity induced by the test compound treatments. To identify and weed out false-positive data, it is essential to perform cytotoxicity analyses for antagonist-mode assays (and inverse-agonist mode assays). INDIGO’s Live Cell Multiplex (LCM) Assay works well for that purpose. However, attempting to normalize RLU data from treated cells in metabolic crisis to untreated, healthy control cells can result in gross misinterpretations of the data when performing cell-based trans-activation assays (which rely on the coordinated cell-cycle processes of gene induction, transcription, translation, mRNA and protein turn-over) “healthy cells” and “dying cells” are not equal units, so attempting to normalize assay data to any cell-related endpoint is not a sound method.

What concentration of organic solvent carried over into the assay wells is acceptable for INDIGO reporter assays?

The concentration of organic solvent carried over into the assay wells should not exceed 0.1%. We recommend no more than 0.4% DMSO carry-over into the assay wells.

View all FAQ

Related Products and Services

In Vitro Toxicity Testing

Gain insight into drug candidates, chemicals, and environmental contaminants by quickly assessing their possible hepatotoxicity.

Luminescent Cell Viability Assay

Be confident in your data knowing that your test compounds and samples are not causing cytotoxicity.

Reporter Assay Services

Explore our screening services and choose your next assay from our extensive portfolio of cell-based receptor assays.